Drug Combination Details
| General Information of the Combination (ID: C72398) | |||||
|---|---|---|---|---|---|
| Name | Asiatic acid NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Cardiomyopathy
[ICD-11: BC43]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | H9c2(2-1) | CVCL_0286 | Healthy | Rattus norvegicus | ||
| In-vivo Model | Male C57BL/6 mice were used in this study. | |||||
| Experimental
Result(s) |
Asiatic acid could attenuate DOX-induced myocardial oxidative stress and apoptosis via activation of the AKT signaling pathway. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Asiatic Acid Protects against Doxorubicin-Induced Cardiotoxicity in Mice. Oxid Med Cell Longev. 2020 May 15;2020:5347204. | |||
